Form 4: Precision BioSciences CEO Michael Amoroso Reports Stock Transactions
SEC Form 4
CEO Michael Amoroso reports vesting of restricted stock units and subsequent sale of shares to cover tax obligations.
Summary
- Michael Amoroso, CEO of Precision BioSciences, reported the vesting of 3,417 Restricted Stock Units (RSUs) on March 21, 2025.
- Following the vesting, Amoroso sold 964 shares of common stock on March 24, 2025, at a price of $5.56 per share.
- The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 2, 2024, to cover tax withholding obligations related to the RSU vesting.
- After these transactions, Amoroso directly owns 109,540 shares of Precision BioSciences common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The filing reflects routine transactions related to executive compensation and tax obligations, executed under a pre-existing plan. There's no indication of unusual or concerning activity.
Positives
- The transactions were part of a pre-planned strategy under Rule 10b5-1, indicating an orderly approach to managing equity compensation.
- The CEO still holds a significant number of shares (109,540), demonstrating continued investment in the company's success.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The use of 10b5-1 plans is a common practice to avoid accusations of insider trading.
Comparison to Industry Standards
- The vesting schedule of the RSUs (three-year annual installments) is a fairly standard practice in the biotech industry for executive compensation.
- The use of a 10b5-1 trading plan is a common and accepted method for executives to manage their stock sales in a transparent and compliant manner, similar to practices seen at companies like CRISPR Therapeutics and Editas Medicine.
Stakeholder Impact
- The sale of shares to cover tax obligations may have a minor, temporary impact on the stock price.
- The disclosure provides transparency to shareholders regarding executive compensation and stock ownership.
Key Dates
| Date | Description |
|---|---|
| 03/21/2022 | Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 21, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. |
| 03/21/2023 | First vesting date of RSUs granted on March 21, 2022. |
| 08/02/2024 | Date of adoption of Rule 10b5-1 trading plan. |
| 03/21/2025 | RSUs vested in full. |
| 03/24/2025 | Sale of 964 shares at $5.56 per share. |
| 03/25/2025 | Date of Form 4 filing. |
Keywords
Form 4, Precision BioSciences, Michael Amoroso, DTIL, Restricted Stock Units, Rule 10b5-1, Insider Trading, SEC Filing, Stock Sale, Vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.